Company Overview and News

2
Investors cautious on trade as ASX closes lower

2018-09-03 theage.com.au
The Australian sharemarket kicked the week off lower, as increased trade war fears rattled the materials sector.
RIO BLT RIO TCL BHPBF NST TPPTY TPM SDA TRAUF NESRF RTPPF TPGTF BHP RIO RTNTF BBL RAP BHP NHRNY BHPLF WNARF WSA

2
Investors cautious on trade as ASX closes lower

2018-09-03 smh.com.au
The Australian sharemarket kicked the week off lower, as increased trade war fears rattled the materials sector.
RIO BLT RIO TCL BHPBF NST TPPTY TPM SDA TRAUF NESRF RTPPF TPGTF BHP RIO RTNTF BBL RAP BHP NHRNY BHPLF WNARF WSA

3
Deals of the day-Mergers and acquisitions

2018-08-30 reuters
Aug 30 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Thursday:
SVTRF VOD CNPAY VOD TCL TRBNW NST TPPTY STRNY CNPAF TPM TRAUF SVT NESRF EBKOF TPGTF VODPF SSUMF NHRNY EBKDY SBGI TRCO CNP TRBAB

2
Deals of the day-Mergers and acquisitions

2018-07-23 reuters
July 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Monday:
BAESY TCL WFAFF APO BAESF ATONV ESL TRAUF WFAFY LPNT BA

19
APA's largest shareholder UniSuper open to joint takeover bid

2018-06-21 theage.com.au
APA’s largest shareholder UniSuper is open to a partnership with the Hong Kong group bidding $13 billion for the gas pipeline company, describing AustralianSuper's decision to team up with the failed private equity bid for hospital group Healthscope as "rational".
RTPPF RIO RIO TCL RIO RTNTF SYD DUETF TRAUF DUE SYDDF

19
APA's largest shareholder UniSuper open to joint takeover bid

2018-06-21 smh.com.au
APA’s largest shareholder UniSuper is open to a partnership with the Hong Kong group bidding $13 billion for the gas pipeline company, describing AustralianSuper's decision to team up with the failed private equity bid for hospital group Healthscope as "rational".
RTPPF RIO RIO TCL RIO RTNTF SYD DUETF TRAUF DUE SYDDF

 
Transurban: Growing Dividend Opportunity

2018-06-14 seekingalpha
Transurban is in the early stages of an international expansion strategy, and early signs are very promising.
TCL TRAUF

19
Should You Invest in the SPDR S&P Global Infrastructure ETF (GII)?

2018-04-27 zacks
Launched on 01/25/2007, the SPDR S&P Global Infrastructure ETF (GII - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Utilities - Infrastructure segment of the U.S. equity market.
ABFOF SQ FMAT GII SQNXF TCL ABRTY UTX TRAUF

1
ASX down after cautious day of trading

2018-04-12 theage.com.au
Geopolitical tensions have given Australian markets their second consecutive day of losses as investors remained cautious over the threat of missile strikes in Syria.
ASXFF IFGNF TCL ASXFY RFGPF IFN ARLUF ALL RFG TRAUF

1
ASX down after cautious day of trading

2018-04-12 smh.com.au
Geopolitical tensions have given Australian markets their second consecutive day of losses as investors remained cautious over the threat of missile strikes in Syria.
ASXFF IFGNF TCL ASXFY RFGPF IFN ARLUF ALL RFG TRAUF

11
Deals of the day-Mergers and acquisitions

2018-03-23 reuters
March 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Friday:
NPSNY FOX WYNN RBNTF TCL DFILF TRAUF NPSN DFIHY RRETY 0700 FOXA RRHI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:TCL / TRANSURBAN GROUP on message board site Silicon Investor.

TCLIF - TTC Technology Corp. TCLIF - TTC Technology Corp. TCLIF - TTC Technology Corp. Techniclone (TCLN) Techniclone (TCLN) Techniclone (TCLN)
MAGC:INTERACTIVE NIGHTCLUBS!!CYBARS.COM MAGC:INTERACTIVE NIGHTCLUBS!!CYBARS.COM MAGC:INTERACTIVE NIGHTCLUBS!!CYBARS.COM CTCK CraftClick.com CTCK CraftClick.com CTCK CraftClick.com
FirstClass Systems FCS - Computer Based Training on Net u0026+ FirstClass Systems FCS - Computer Based Training on Net u0026+ FirstClass Systems FCS - Computer Based Training on Net u0026+ Technology Stocks SEPR MMGR GLC FONR Interesting NetArtcls Technology Stocks SEPR MMGR GLC FONR Interesting NetArtcls Technology Stocks SEPR MMGR GLC FONR Interesting NetArtcls
STCL - Shared Technologies Cellulat STCL - Shared Technologies Cellulat STCL - Shared Technologies Cellulat Utah Clay Technology, Inc. UTCL (Small Float) Utah Clay Technology, Inc. UTCL (Small Float) Utah Clay Technology, Inc. UTCL (Small Float)